← Leaderboards
Carol S Lim
Utah State Higher Education System--University Of Utah
$5,461,677
Attributed
$5,461,677
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $595.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,461,677 · 6
By mechanism
R01$4,310,622 · 3
R21$1,151,055 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionProteinsCellsApoptoticApoptosisMalignant NeoplasmsIn VivoMutantGene TherapyCell NucleusCaspaseSpecificityNuclearLocationClinically RelevantLeukemic CellMutateOncogenicAmino AcidsCell LineLengthDimerizationCell KillingGenes
Grant awards (20)
A Leukemia Cell-Specific Coiled-Coil Protein for Treatment of Chronic Myeloid Leukemia$348,844
R01 · FY2025 · CA · contact PI
A Leukemia Cell-Specific Coiled-Coil Protein for Treatment of Chronic Myeloid Leukemia$331,402
R01 · FY2024 · CA · contact PI
A Leukemia Cell-Specific Coiled-Coil Protein for Treatment of Chronic Myeloid Leukemia$341,867
R01 · FY2023 · CA · contact PI
A Leukemia Cell-Specific Coiled-Coil Protein for Treatment of Chronic Myeloid Leukemia$341,867
R01 · FY2022 · CA · contact PI
Re-engineered Mitochondrially Targeted p53 Gene Therapy in Liver Cancer$209,604
R21 · FY2022 · CA · contact PI
A Leukemia Cell-Specific Coiled-Coil Protein for Treatment of Chronic Myeloid Leukemia$348,844
R01 · FY2021 · CA · contact PI
Re-engineered Mitochondrially Targeted p53 Gene Therapy in Liver Cancer$178,234
R21 · FY2021 · CA · contact PI
Mitochondrially Targeted p53 DBD for Treatment of Ovarian Cancer$194,445
R21 · FY2016 · CA · contact PI
Mitochondrially Targeted p53 DBD for Treatment of Ovarian Cancer$162,038
R21 · FY2015 · CA · contact PI
Simultaneous Targeting of p53 to the Nucleus and Mitochondria for Cancer Therapy$282,853
R01 · FY2013 · CA · contact PI
Simultaneous Targeting of p53 to the Nucleus and Mitochondria for Cancer Therapy$300,906
R01 · FY2012 · CA · contact PI
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences$275,034
R01 · FY2012 · CA · contact PI
Simultaneous Targeting of p53 to the Nucleus and Mitochondria for Cancer Therapy$301,073
R01 · FY2011 · CA · contact PI
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences$275,147
R01 · FY2011 · CA · contact PI
Simultaneous Targeting of p53 to the Nucleus and Mitochondria for Cancer Therapy$312,288
R01 · FY2010 · CA · contact PI
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences$283,656
R01 · FY2010 · CA · contact PI
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences$283,656
R01 · FY2009 · CA · contact PI
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences$283,185
R01 · FY2008 · CA · contact PI
Controlled Targeting of Proteins to Cell Compartments$182,484
R21 · FY2006 · DK · contact PI
Controlled Targeting of Proteins to Cell Compartments$224,250
R21 · FY2005 · DK